Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Visa to Move European Headquarters to London’s Canary Wharf 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
SK Biopharmaceutical is eyeing a share of the 4 trillion won US antiepileptic drug market with its cenobamate tablet Xcopri, which treats partial-onset seizures in adults.
The drug, approved by the US Food and Drug Administration (FDA) on November 21 last year, provides an extra needed treatment option for people with seizures.
Xcopri is the first Korean novel drug, researched and developed entirely and independently by a Korean pharma firm, notes SK Biopharmaceutical CEO Cho.
It is a product of Cho's 15-year research and development drive.
According to the US FDA, the safety and efficacy of XCOPRI were established in two studies that enrolled 655 adults, which were randomized, double-blind, and placebo-controlled.
The FDA granted Xcopri's approval to SK Life Science Inc., the US arm of SK Biopharmaceutical.
Thus, SK Life Science will undertake the US distribution of Xcopri.
